Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: Prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine

The changes of plasma amyloid beta (Abeta42) protein, homocysteine and medial temporal lobe atrophy (MTA) were studied by the transition from cognitive health to mild cognitive impairment (MCI) and to Alzheimer's disease (AD) in a prospective cohort of individuals aged 75 years. MTA but not plasma Abeta42 measured at baseline predicted which persons remained cognitively healthy (CH) and who developed AD 2.5 years later. The increase of plasma Abeta42 over time significantly distinguished between persons who remained CH on the one hand and MCI converters and AD converters out of cognitive health on the other (CH-to-MCI and CH-to-AD converters). Although both groups showed similar increase of Abeta42 levels, CH-to-AD converters had a higher increase of homocysteine compared to CH-to-MCI converters or to persons remaining CH. In comparison to all cognitive subgroups, the AD converters from MCI at baseline showed the smallest increase of Abeta42 levels and rather no increase of homocysteine. In logistic regression analysis, the increase of plasma Abeta42 but not change of MTA significantly predicted the conversion from CH to MCI, and changes of MTA and homocysteine but not of plasma Abeta42 predicted the conversion from CH to AD. The increase of plasma Abeta42 correctly allocated CH-to-MCI and CH-to-AD converters with low (63%) specificity (for both) and low (60%) sensitivity (54% for AD group). These results indicate that (1) plasma Abeta42 alone is not suitable as a biomarker for AD, (2) in the course of cognitive deterioration of the AD-type the increase of plasma Abeta42 seems to be an initial event, (3) similar to cerebrospinal fluid, changes of plasma Abeta42 may reflect the transition from cognitive health to AD, and (4) whether persons with MCI develop AD may depend on an accumulation of further toxic metabolites such as homocysteine.

[1]  S. DeKosky,et al.  Mild cognitive impairment, amnestic type , 2004, Neurology.

[2]  G. C. Román,et al.  Vascular dementia , 1993, Neurology.

[3]  B. Zlokovic.  Clearing amyloid through the blood–brain barrier , 2004, Journal of neurochemistry.

[4]  P. Mehta,et al.  Plasma amyloid β protein 1–42 levels are increased in old Down Syndrome but not in young Down Syndrome , 2003, Neuroscience Letters.

[5]  D. Holtzman,et al.  IgG-Assisted Age-Dependent Clearance of Alzheimer's Amyloid β Peptide by the Blood–Brain Barrier Neonatal Fc Receptor , 2005, The Journal of Neuroscience.

[6]  Antonio Federico,et al.  Cerebrospinal fluid tau, Aß, and phosphorylated tau protein for the diagnosis of Alzheimer's disease , 2006, Journal of cellular physiology.

[7]  R. Deane,et al.  RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid &bgr;-Peptide Clearance Through Transport Across the Blood–Brain Barrier , 2004, Stroke.

[8]  P. Mehta,et al.  Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease , 2001, Neuroscience Letters.

[9]  R. Reitan.  Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .

[10]  P Julin,et al.  Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study , 2000, Journal of neurology, neurosurgery, and psychiatry.

[11]  M. Inglese,et al.  Plasma levels of amyloid β-protein 42 are increased in women with mild cognitive impairment , 2004, Neurology.

[12]  C. Jack,et al.  Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. , 2004, Archives of neurology.

[13]  S. Gandy,et al.  Systemic Catabolism of Alzheimer's Aβ40 and Aβ42* , 2004, Journal of Biological Chemistry.

[14]  A. Hofman,et al.  Plasma amyloid β, apolipoprotein E, lacunar infarcts, and white matter lesions , 2004, Annals of neurology.

[15]  A. Monsch,et al.  Normal ranges of neuropsychological tests for the diagnosis of Alzheimer's disease. , 2000, Studies in health technology and informatics.

[16]  B. Hyman,et al.  Amyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma* , 1996, The Journal of Biological Chemistry.

[17]  R. Tanzi,et al.  Clearance of Alzheimer's Aβ Peptide The Many Roads to Perdition , 2004, Neuron.

[18]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[19]  D. Holtzman,et al.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.

[20]  K. Blennow,et al.  Unaltered Plasma Levels of β-Amyloid(1–40) and β-Amyloid(1–42) upon Stimulation of Human Platelets , 2003, Dementia and Geriatric Cognitive Disorders.

[21]  I. Kloszewska,et al.  Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. , 2005, Acta neurobiologiae experimentalis.

[22]  Sudha Seshadri,et al.  Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease , 2002 .

[23]  I. Rosenberg,et al.  Hyperhomocysteinemia associated with poor recall in the third National Health and Nutrition Examination Survey. , 2001, The American journal of clinical nutrition.

[24]  I. Bell,et al.  Plasma homocysteine in vascular disease and in nonvascular dementia of depressed elderly people , 1992, Acta psychiatrica Scandinavica.

[25]  Don L. Armstrong,et al.  Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease , 2005, Nature Medicine.

[26]  J. Growdon,et al.  Association of homocysteine with plasma amyloid β protein in aging and neurodegenerative disease , 2005, Neurology.

[27]  P. Fischer,et al.  Subjective Memory Complaints and Objective Memory Impairment in the Vienna‐Transdanube Aging Community , 2004, Journal of the American Geriatrics Society.

[28]  J. Blangero,et al.  Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. , 2000, Science.

[29]  P. Scheltens,et al.  Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[30]  C. Gottfries,et al.  Identification of Cognitive Impairment in the Elderly: Homocysteine Is an Early Marker , 1998, Dementia and Geriatric Cognitive Disorders.

[31]  J. Growdon,et al.  Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels , 2003 .

[32]  T. Lanz,et al.  Studies of Aβ Pharmacodynamics in the Brain, Cerebrospinal Fluid, and Plasma in Young (Plaque-Free) Tg2576 Mice Using the γ-Secretase Inhibitor N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575) , 2004, Journal of Pharmacology and Experimental Therapeutics.

[33]  M. Emmerling,et al.  High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. , 1999, Biochemical and biophysical research communications.

[34]  J. Morris,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.

[35]  P. Fischer,et al.  Vienna Transdanube Aging "VITA": study design, recruitment strategies and level of participation. , 2002, Journal of neural transmission. Supplementum.

[36]  K. Blennow,et al.  Marked increase of β-amyloid(1–42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury , 2004, Journal of Neurology.

[37]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[38]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[39]  Anders Wallin,et al.  Amino-Truncated β-Amyloid42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment , 2005 .

[40]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[41]  P. Riederer,et al.  Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia , 2005, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[42]  S. Zehetmayer,et al.  VITA: subtypes of mild cognitive impairment in a community‐based cohort at the age of 75 years , 2005, International journal of geriatric psychiatry.

[43]  B Engvall,et al.  Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression , 1999, Annals of neurology.

[44]  K. Blennow,et al.  Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma , 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[45]  A. Spiro,et al.  Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. , 1996, The American journal of clinical nutrition.

[46]  M. Reger,et al.  Preserved Cognition in Patients With Early Alzheimer Disease and Amnestic Mild Cognitive Impairment During Treatment With Rosiglitazone: A Preliminary Study , 2005 .

[47]  R. Tanzi,et al.  Clearance of Alzheimer's Aβ PeptideThe Many Roads to Perdition , 2004 .

[48]  Giovanni B. Frisoni,et al.  Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .

[49]  D. Holtzman,et al.  Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease , 2002, Science.

[50]  R. Mayeux,et al.  Plasma A&bgr;40 and A&bgr;42 and Alzheimer’s disease: Relation to age, mortality, and risk , 2003 .

[51]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[52]  G. Kemmler,et al.  Plasma amyloid β protein 42 in non-demented persons aged 75 years: Effects of concomitant medication and medial temporal lobe atrophy , 2005, Neurobiology of Aging.

[53]  Ann Marie Schmidt,et al.  RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.

[54]  F Barkhof,et al.  The Diagnostic Value of Magnetic Resonance Imaging and Technetium 99m‐HMPAO Single‐Photon-Emission Computed Tomography for the Diagnosis of Alzheimer Disease in a Community‐Dwelling Elderly Population , 1997, Alzheimer disease and associated disorders.